Executive Director’s Message
Our mission is to improve the health status of families infected and affected by HIV/AIDS through research, training, prevention and care.
Isoniazid preventive therapy (IPT) initiation during pregnancy was associated with increased incidence of adverse pregnancy outcomes in the TB APPRISE trial. Effects of in utero IPT exposure on infant growth are unknown. Co-author Dr. Deo Wabwire contributes to this analysis of data from the TB APPRISE (IMPAACT P1078) trial in eight countries with high tuberculosis prevalence. Click here to read the article.
March 11, 2023
HIV status disclosure among sexual partners is vital in HIV management. Community health workers support HIV disclosure among adults living with HIV in sexual relationships with disclosure difficulties. Dr. Zubair Lukyamuzi writes about the experiences faced in using this model in rural Uganda. Click here to read the article.
January 23, 2023
Antiretroviral therapy (ART) is associated with high rates of adverse birth outcomes, including preterm birth and low birthweight. Studies suggest that progesterone and prolactin may play important intermediary roles. Click here to read more on this data analysis from the PROMISE trial in an article co-authored by Dr. Maxensia Owor.
December 28, 2022
Pre-treatment HIV drug resistance is a threat to elimination of mother to child HIV transmission and could lead to virological failure among HIV-positive pregnant women. Dr. Alexander Amone et al analyze the genotypic HIV drug resistance (HIVDR) of baseline samples of participants enrolled in the Option B+ clinical trial in Uganda. Click here to read the article.